Role of vertical circulating exosomes biomarkers in preeclampsia

Abstract

Preeclampsia, a hypertensive disorder of pregnancy, poses significant risks to maternal and fetal health. Recent research highlights the potential of vertical circulating exosomes (VCEs) as biomarkers for early detection and monitoring of preeclampsia. Exosomes, small extracellular vesicles involved in intercellular communication, carry bioactive molecules that are messengers of the parental cell status (healthy or undergoing any pathological condition). In preeclampsia, alterations in the cargo of VCEssuch as proteins, lipids, and nucleic acids play the role of biomarkers in pathophysiology complications. These exosomal contents can provide insights into the underlying mechanisms, including endothelial dysfunction, immune response dysregulation, and placental abnormalities. Early identification of specific exosomal biomarkers may facilitate timely therapeutic interventions, improving outcomes for both mother and child. This article explores the emerging role of VCEs in preeclampsia, emphasizing their diagnostic and prognostic potential, and underscores the need for further research to validate these biomarkers and integrate them into clinical practice.

Keywords

Exosomes / Placental exosomes / Preeclampsia / Biomarkers

References

[1] Braunthal S, Brateanu A. Hypertension in pregnancy: pathophysiology and treatment. SAGE Open Med. 2019;7:2050312119843700.

[2] Chang KJ, Seow KM, Chen KH. Preeclampsia: recent advances in predicting, preventing, and managing the maternal and fetal life-threatening condition. Int J Environ Res Public Health. 2023;20(4):2994.

[3] Souza JP, Bellissimo-Rodrigues F, Santos LLD. Maternal mortality: an eco-social phenomenon that calls for systemic action. Rev Bras Ginecol Obstet. 2020;42(4):169-173.

[4] Kashyap N, Pradhan M, Singh N, Yadav S. Early detection of fetal malformation, a long distance yet to cover! Present status and potential of first trimester ultrasonography in detection of fetal congenital malformation in a developing country: experience at a tertiary care centre in India. J Pregnancy. 2015;2015:623059.

[5] Shan Y, Hou B, Wang J, Chen A, Liu S. Exploring the role of exosomal MicroRNAs as potential biomarkers in preeclampsia. Front Immunol. 2024;15:1385950.

[6] Ghafourian M, Mahdavi R, Akbari Jonoush Z, et al. The implications of exosomes in pregnancy: emerging as new diagnostic markers and therapeutics targets. Cell Commun Signal. 2022;20(1):51.

[7] Salomon C, Guanzon D, Scholz-Romero K, et al. Placental exosomes as early biomarker of preeclampsia: potential role of exosomal microRNAs across gestation. J Clin Endocrinol Metab. 2017;102(9):3182-3194.

[8] Dimitriadis E, Rolnik DL, Zhou W, et al. Pre-eclampsia. Nat Rev Dis Primers. 2023;9(1):8.

[9] Hromadnikova I, Kotlabova K, Ivankova K, Krofta L. First trimester screening of circulating C19MC microRNAs and the evaluation of their potential to predict the onset of preeclampsia and IUGR. PLoS One. 2017;12(2):e0171756.

[10] Agnihotram R, Dhar R, Dhar D, Purushothaman K, Narasimhan AK, Devi A. Fusion of exosomes and nanotechnology: cutting-edge cancer theranostics. ACS Appl Nano Mater. 2024;7(8):8489-8506.

[11] Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021;19(1):47.

[12] Lee S, Gonzalez-Suarez AM, Huang X, et al. Using electrochemical immunoassay in a novel microtiter plate to detect surface markers of preeclampsia on urinary extracellular vesicles. ACS Sens. 2023;8(1):207-217.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.